BRÈVE

sur Xybion Digital Inc (isin : CA98423T1093)

Envol Biomedical Partners with Xybion to Digitize Lab Operations

Envol Biomedical has chosen Xybion Digital’s Pristima LIMS to revolutionize its lab operations, enhancing the efficiency and integrity of its data across preclinical and clinical research. Announced on April 15, 2024, this collaboration aims to provide end-to-end process standardization in EnvolBio’s laboratories.

The integration of Xybion's software is expected to support EnvolBio's specialized services in drug discovery, toxicology, and clinical trials by managing study planning, execution, and regulatory submissions through a unified digital platform. This will simplify the IT ecosystem and enhance the business user experience by reducing reliance on multiple systems.

Jacob McDonald, CEO of EnvolBio, expressed enthusiasm for the partnership, highlighting the potential for increased operational flexibility and efficiency. Meanwhile, Kamal Biswas, COO of Xybion, emphasized the suite's capabilities in streamlining workflows and expanding the use of artificial intelligence and automation in lab environments.

Dr. Pradip Banerjee, Xybion Digital's CEO, reflected on the partnership as a testament to Xybion's commitment to advancing digital solutions in the life sciences sector, further solidifying its position as a trusted partner to leading global corporations.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Xybion Digital Inc